Hepatocellular carcinoma associated with budd-chiari syndrome: imaging features and transcatheter arterial chemoembolization

BMC Gastroenterology

Yan Wang¹  Peng Song¹  Qing-Sheng Fan¹  Feng Duan¹  Mao-Qiang Wang¹  Feng-Yong Liu¹ 

[1] Department of Interventional Radiology, Chinese People’s Liberation Army General Hospital, 28 Fuxing Road, Beijing 100853, China

关键词: Transcatheter arterial chemoembolization;    Budd–Chiari syndrome;    Hepatocellular carcinoma;   

Others  :  857868
DOI  :  10.1186/1471-230X-13-105

 received in 2012-12-10, accepted in 2013-06-10,  发布年份 2013

【 摘 要 】

Background

Budd–Chiari syndrome (BCS) often leads to hepatocellular carcinoma (HCC). Transcatheter arterial chemoembolization (TACE) has been increasingly used to treat BCS patients with HCC. The purposes of this study were to illustrate imaging features in BCS patients with HCC, and to analyze the effects of TACE on BCS patients with HCC.

Methods

246 consecutive patients with primary BCS were retrospectively studied. 14 BCS patients with HCC were included in this study. BCS were treated with angioplasty and/or stenting, and HCC were managed with TACE. Imaging features on ultrasonography, CT, MRI, and angiography and the serum AFP level were analyzed.

Results

Inferior vena cava block and stricture of hepatic venous outflow tract more frequently occurred. Portal vein invasion was found in only 2 patients (14.2%). Imaging studies showed that most nodules of HCC were near the edge of liver, irregular, more than 3 cm in diameter, heterogeneous mass and solitary (≤3 nodules). HCC in patients associated with BCS was isointense or hypointense in nonenhanced CT images, and exhibited heterogeneous enhancement during the arterial phase and washout during the portal venous phase on enhanced CT and MRI. The serum AFP level significantly declined after TACE treatment.

Conclusions

BCS patients with inferior vena cava block and stricture of hepatic venous outflow tract seems to be associated with HCC. A single, large, irregular nodule with a peripheral location appears to be HCC. TACE can effectively treat HCC in BCS patients.

【 授权许可】

   
2013 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Menon KV, Shah V, Kamath PS: The budd-chiari syndrome. N Engl J Med 2004, 350:578-585.
• [2]Aydinli M, Bayraktar Y: Budd-chiari syndrome: etiology, pathogenesis and diagnosis. World J Gastroenterol 2007, 13:2693-2696.
• [3]Valla DC: Primary budd-chiari syndrome. J Hepatol 2009, 50:195-203.
• [4]Shin SH, Chung YH, Suh DD, Shin JW, Jang MK, Ryu SH, Park NH, Lee HC, Lee YS, Suh DJ: Characteristic clinical features of hepatocellular carcinoma associated with budd-chiari syndrome: evidence of different carcinogenic process from hepatitis B virus-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004, 16:319-324.
• [5]Valla DC: The diagnosis and management of the budd-chiari syndrome: consensus and controversies. Hepatology 2003, 38:793-803.
• [6]Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC: Budd-chiari syndrome: a review by an expert panel. J Hepatol 2003, 38:364-371.
• [7]Katoh M, Shigematsu H: Primary liver carcinoma complicating membranous obstruction of the inferior vena cava. Pathol Int 1999, 49:253-257.
• [8]Singh V, Sinha SK, Nain CK, Bambery P, Kaur U, Verma S, Chawla YK, Singh K: Budd-chiari syndrome: our experience of 71 patients. J Gastroenterol Hepatol 2000, 15:550-554.
• [9]Gwon D 2nd, Ko GY, Yoon HK, Sung KB, Kim JH, Lee SS, Lee JM, Ohm JY, Shin JH, Song HY: Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence, characteristics, and risk factors and clinical efficacy of TACE. Radiology 2010, 254:617-626.
• [10]Kawaguchi T, Sata M, Ono N, Sakisaka S, Koga H, Ijuin H, Mitsuyama K, Ueno T, Kage M, Tanikawa K: Budd-chiari syndrome complicated by hepatocellular carcinoma with no evidence of infection with hepatitis virus: a case report. Hepatogastroenterology 1999, 46:3237-3240.
• [11]Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol 2001, 35:421-430.
• [12]Daniele B, Bencivenga A, Megna AS, Tinessa V: Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004, 127:S108-S112.
• [13]Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
• [14]Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, et al.: Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008, 47:97-104.
• [15]Lee KH, Sung KB, Lee DY, Park SJ, Kim KW, Yu JS: Transcatheter arterial chemoembolization for hepatocellular carcinoma: anatomic and hemodynamic considerations in the hepatic artery and portal vein. Radiographics 2002, 22:1077-1091.
• [16]Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
• [17]Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
• [18]Moucari R, Rautou PE, Cazals-Hatem D, Geara A, Bureau C, Consigny Y, Francoz C, Denninger MH, Vilgrain V, Belghiti J, et al.: Hepatocellular carcinoma in budd-chiari syndrome: characteristics and risk factors. Gut 2008, 57:828-835.
• [19]Vilgrain V, Lewin M, Vons C, Denys A, Valla D, Flejou JF, Belghiti J, Menu Y: Hepatic nodules in budd-chiari syndrome: imaging features. Radiology 1999, 210:443-450.
• [20]Aoki K, Miyamoto T, Murata H, Kawahara K, Oka Y, Maeda S, Yamashita K: Significance of accessory hepatic venography to evaluate the intrahepatic venous system for obstruction of the inferior vena cava at the hepatic portion with main hepatic vein obstruction. Nihon Geka Gakkai Zasshi 1986, 87:704.
• [21]Simson IW: Membranous obstruction of the inferior vena cava and hepatocellular carcinoma in south africa. Gastroenterology 1982, 82:171-178.
• [22]Dilawari JB, Bambery P, Chawla Y, Kaur U, Bhusnurmath SR, Malhotra HS, Sood GK, Mitra SK, Khanna SK, Walia BS: Hepatic outflow obstruction (budd-chiari syndrome). experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994, 73:21-36.
• [23]Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-S50.
• [24]Valla D: Hepatic venous outflow tract obstruction etiopathogenesis: asia versus the west. J Gastroenterol Hepatol 2004, 19:S204-S211.
• [25]Brancatelli G, Federle MP, Grazioli L, Golfieri R, Lencioni R: Benign regenerative nodules in budd-chiari syndrome and other vascular disorders of the liver: radiologic-pathologic and clinical correlation. Radiographics 2002, 22:847-862.
• [26]Winston CB, Schwartz LH, Fong Y, Blumgart LH, Panicek DM: Hepatocellular carcinoma: MR imaging findings in cirrhotic livers and noncirrhotic livers. Radiology 1999, 210:75-79.
• [27]Brancatelli G, Vilgrain V, Federle MP, Hakime A, Lagalla R, Iannaccone R, Valla D: Budd-chiari syndrome: spectrum of imaging findings. AJR Am J Roentgenol 2007, 188:W168-W176.
• [28]Chen MF, Hwang TL, Jeng LB, Wang CS, Jan YY, Chen SC: Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Surg 1994, 129:738-742.
• [29]Llovet JM, Fuster J, Bruix J: The barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004, 10:S115-S120.
• [30]Bruix J, Sala M, Llovet JM: Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004, 127:S179-S188.
• [31]Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP: Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005, 92:1862-1868.
• [32]Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, et al.: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006, 131:461-469.
• [33]Hatanaka Y, Yamashita Y, Takahashi M, Koga Y, Saito R, Nakashima K, Urata J, Miyao M: Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology 1995, 195:747-752.
• [34]Savastano S, Miotto D, Casarrubea G, Teso S, Chiesura-Corona M, Feltrin GP: Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child’s grade a or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol 1999, 28:334-340.